Background: Current developments in the targeted therapies of non-small-cell lung carcinoma demand accurate classification to dodge the adverse drug response and to yield maximum therapeutic outcome. Accurate classification depends on the classical hematoxylin and eosin staining and immunohistochemistry techniques. In selected critical cases, inter-observer variability, lack of standardization, tumor heterogeneity, and degree of differentiation makes it difficult to classify NSCLC. During the last decade, microRNAs (miRNAs) have been proven to be a promising biomarker in the field of oncology from diagnosis to therapy. The present study developed a binary classification method based on the expression of three well-known miRNAs: miR-205, miR-196b, miR-375, since it is the most demanding criteria to the clinicians trying to provide better therapy to the patients. Methods: Quantitative real-time polymerase chain reaction was performed for 90 NSCLC samples. Receiver-Operator Characteristic Curve and Discriminant Function Analysis was done to classify the NSCLC. A discriminant formula was developed to calculate the Z-score of miR-375 (Z3 = −0.637 + (0.439 x NCt miR-375 ) + (−0.245 x NCt miR-21 ).
Background
Lung cancer (LC) is the leading cause of cancer-related death worldwide and contributed to 12.9% of all new cancer cases diagnosed in 2012 [1] . The most common form of lung cancer is the Non-Small-Cell Lung Cancer (NSCLC), which accounts for 85-90% of all lung carcinoma [2] . There are two subtypes of NSCLC: Adenocarcinoma (ADCC), and Squamous Cell Carcinoma (SQCC). Traditional therapy considered NSCLC as a single homogeneous entity. However, targeted therapy changed this idea. The therapeutic response of ADCC and SQCC was different to chemo / targeted therapies. For instance, EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor therapy showed promising outcomes only for those who had mutated EGFR allele, prevalent in ADCC. Anaplastic lymphoma kinase (Alk) translocation positive ADCCs, showed high sensitivity to crizotinib therapy [3] . The clinical outcome of cisplatin/ pemetrexed therapy to ADCC patients was far better than cisplatin/gemcitabine therapy [4] . Due to angiogenic heterogeneity and proliferative behavior, SQCC poses a threat in the clinic and there is a recognized high need for new therapies for SQCC [5] . Hence, accurate classification of NSCLC became mandatory to facilitate a better outcome.
Till date, NSCLC classification is majorly dependent on hematoxylin-eosin staining (HE) and immunohistochemistry (IHC). In 33% of critical cases due to tumor cell paucity in the absence of tissue architecture, or poor differentiation an adjunctive molecular assay side by side with IHC will help clinicians to classify NSCLC better. 10-30% NSCLC tends to be left as Not Otherwise Specified (NOS) even after a careful examination under the microscope by expert pathologists, due to the difficulties in translating all the morphogenic features available from the cytology/biopsy samples [6] . Hence an adjunctive method is necessary to confirm the NSCLC classification in selected cases.
During last few decades, scientists and clinicians have been hunting for molecular markers which could provide an unbiased classification of NSCLC. It has been long believed and recently proven that miRNAs express differentially in several types of cancers and promising biomarker for NSCLC classification. One study successfully identified ADCC and SQCC by using miR-205 expression level in the western population [7] , and another study established a panel of three microRNAs (miR-205, miR-196b, and miR-375) to execute the same function in the Japanese population [8] . Interestingly, the idea of miR-205 as a promising biomarker to identify SQCC and ADCC in any ethnic group was refuted by a study from Italy [9] . It is possible that the expression pattern of a particular miRNA can vary from one ethnicity to another. Hence, it was very important to understand that which microRNAs are the best suitable markers for NSCLC sub-classification in Indian NSCLC patients. In the present study hypothesized that expression of miR-205, miR-196b, and miR-375 might not be the same as other populations, and so the biomarker for NSCLC classification may vary. To the best of our knowledge, this is the first study to evaluate the role of miR-205, miR-196b, and miR-375 to classify NSCLC in Indian lung cancer patients.
Methods
The present study was conducted at the Research and Development Division of SRL Ltd., Mumbai, India. The study included 90 formalin-fixed-paraffin-embedded (FFPE) tumor samples from lung lesions, bronchial [10] . Briefly, the HE-stained slides were initially looked for the absence of keratinization or intercellular bridges and/or Thyroid transcription factor 1 (TTF1) positive staining to identify ADCC (Fig. 1) . Similarly, the presence of intercellular bridges and/or P63 positive staining were the key criteria for diagnosing SQCC (Fig.  1 ). Leica auto Steiner was used for HE staining, and IHC was done manually. In the case of any disagreement, the consensus was achieved by reviewing the cases with third independent histopathologists. Schematic diagram of experimental strategy is shown in Fig. 2 .
RNA isolation
Total RNA including small RNA was extracted using mirVana™ miRNA Isolation Kit (Ambion) as per the manufacturer's instructions. Before RNA isolation, separate HE slides were reviewed by a pathologist to assure 50% tumor content is suitable for RNA isolation. At least 10 mg tissue was processed for RNA isolation of NSCLC, tumor differentiation grade, as suitable for RNA extraction. [11] . In the Mann-Whitney test, box and whisker plot analysis were done to observe the difference in sample score between SQCC and ADCC for each miRNA (Fig. 3) . ROC curves were plotted to determine the cut-off values for each miRNA (Fig. 4) . Cut-off values differentiating SQCCs and ADCCs pointed out the youden index (sensitivity + specificity -1) in ROC plot. The Z score was calculated using Discriminant Function Analysis (DFA), which is more profound and unbiased than ROC analysis [8] . A discriminant score is based on the weighted combination of the independent variables. Discriminant score = a + b1X1 + b2X2 + ……. + bnXn. "X" is the predictor and "b" is the discriminant 
qRT-PCR

Results
Clinical characteristics of NSCLC patients
The present study analyzed 90 tumor tissues from NSCLC patients. Table 1 represents the clinical characteristics of all patients, and male NSCLC cases (71, 78.9%) were higher than those of female (19, 21.1%).
There was a significant trend of increased number of SQCC in male patients (41, 89.1%) in comparison with female patients (5, 10.9%). The frequency of NSCLC cases was higher in older patients (≥60 years, n = 50, 55.6%) than those of younger patients (<60 years, n = 40, 44.4%). The median age of the cohort was 61 years, ranging from 34 to 85 years. Distributions across various Most of the tumor samples were poorly differentiated (PD) (44, 48.9%), and 33 (36.7%) were moderately differentiated (MD), while only 14 (15.5%) cases were well differentiated (WD). The sample cohort was divided into a training set (n = 30) and a validation set (n = 60) ( Table 1) .
Optimization of miR-205, miR-196b, miR-375 to classify NSCLC with the ROC and DFA Initially, the expression levels of miR-205, miR-196b, and miR-375, miR-21 and U6 snRNA of 30 samples (Training set) were measured in duplicate to investigate the appropriate miRNAs for NSCLC subtyping. There was a trend of increased Ct value of miR-375 in SQCC compared to ADCC (p = 0.0478, Table 3 ), while the miR-205 and miR-196b showed no significant difference between Ct value among SQCC and ADCC (Table 3 ).
There was no significant difference between miR-21 Ct value among SQCC and ADCC (p = 0.965). Average Ct of miR-21 in ADCC was 20.66 and in SQCC was 20.58. Ct value of each miRNA was normalized by subtracting the Ct value of U6 snRNA. The normalised Ct value was used to calculate the sample score (Sample score = AvgCt miR -[(AvgCt miR-21 + AvgCt U6 )/2] = NCt miR -(NCt miR-21 /2)). As all the sample scores from both groups were independent and ordinal, the MannWhitney test revealed that there was a significant difference between the median score of SQCC and ADCC for miR-375 (Median of SQCC = 0.4745, Median of ADCC = 1.682, p < 0.0001) ( Table 3 , Fig. 3a ). There were no significant differences observed between the SQCC and ADCC for miR-205 (p = 0.5875) and miR196b (p = 0.9908) ( Table 3 , Fig. 3a) . ROC curve was generated for each miRNA, and the Area Under Curve (AUC) of the three miRNAs were as follows: miR-205 -0.471, miR-196b -0.498, miR-375 -0.907 (Fig. 4) . As the AUC represented the accuracy of the test, it clearly showed that only miR-375 provided better accuracy, as compared to miR-205 and miR-196b. Also, a cutoff was set at 0.584 for miR-375 with a test sensitivity of 93.33% and specificity of 86.67% (Table 3) , and the (Table 4) The sample sorted number versus Score miR plots corroborated the findings of ROC analysis (Fig. 5 ). Both the groups (SQCC and ADCC) were evenly distributed on the both sides of the cut-off line in the case of miR-375 (Fig. 5c ), but not in the case of miR-205 and miR-196b (Fig. 5a, b) . Discriminant analysis calculated the z-value using normalized Ct of single and multiple miRNAs, which revealed 93.3% test sensitivity and 86.7% test specificity for miR-375 (Table  5 , Fig. 6a, c) . Sensitivity and specificity of miR-205 and miR-196b were very poor compared to miR-375 (Table  5) . ROC and DFA both showed similar PPV (87.5%, 95% CI = 61.65%-98.45%), NPV (92.86%, 95% CI = 66.13%-99.82%), and DOR (91, 7.3-1126.9) ( Table 6 ). Fig. 3b ). The cut-off value, established by the ROC and DFA for each miRNAs, were used to differentiate SQCC from ADCC in the validation set (n = 60), which provided a test sensitivity of 96.7% and specificity of 93.1% for miR-375 (Fig. 6b, d) . The validation set produced a similar outcome as the training Mann-Whitney test was done to check the significant difference between the median sample score of SQCC and ADCC for the training set and validation set (Table 7) .
Discussion
Initially, miR-375 was discovered as a key player in glucose metabolism and insulin secretion [12, 13] , and was later found to be associated with tumorigenesis and deregulated in several types of cancer. Growing evidence suggested that it was down-regulated in esophageal SQCC, Barrett's carcinoma, glioma, colorectal cancer, hepatocellular carcinoma, lung cancer, and associated with advanced-stage metastasis and unfavorable treatment outcome [14] [15] [16] [17] . Also, evidence from the previous study suggested that miR-375 plays a dual role in NSCLC as it was over-expressed in ADCC and suppressed in SQCC, proving the oncogenic nature in ADCC and tumor suppressor in SQCC [18] . This evidence accentuated the principal role of miR-375 tumorigenesis, and the current study found significant up-regulation of miR-375 in ADCC and downregulation in SQCC, which is consistent with the previous findings. In the present study, a diagnostic method was developed based on the growing evidence which highlighted the significance of miR-205, miR-196b, miR-375 as molecular markers for the binary classification of NSCLC. Recent evidence on miR-375 expression in SQCC and ADCC were consistent with the present study. Lebanony et al. [7] investigated and developed a diagnostic method of NSCLC classification based on . Cut-off value = "Zero". If the Z score was positive, sample was designated as SQCC and negative sample was designated as ADCC. Z score was calculated with the help of the formulas mentioned in the Table 2 . True positive: Samples which were diagnosed as SQCC by the histopathologists and with positive Z score. False negative: Samples which were characterised as SQCC but with negative Z score. True negative: Samples which were characterised as ADCC by histopathologists and with negative Z score. False negative: Samples which were initially classified as ADCC but with the positive Z score miR-205, and Patnaik et al. [19] proved the diagnostic ability of miR-205 and miR-375. Later, the classifying role of this miR-205 was dismissed by another study [9] . Hamamoto et al. [8] emphasized the diagnostic role of a panel of miRNAs including miR-205, miR-196b, miR-375. The role of miR-205 as an individual biomarker for NSCLC classification was arguable as contradictory evidence were reported earlier [9] . The present study developed a diagnostic method based on differential expression of miR-375 to classify NSCLC into SQCC and ADCC. It not only included ROC and DFA but also calculated PPV, NPV, and DOR to achieve more comprehensive and excellent accuracy, enabling clinicians to better identify SQCC and ADCC with the help of miR-375 and with the additional contribution by miR-21. Interestingly in the present study, Ct value of miR-21 did not vary significantly among SQCC and ADCC (Training set: p = 0.9658 Validation set: p = 0.4367). miR-375 plays a key role in cancer development and Epithelial Mesenchymal Transition (EMT) pathway by targeting ELAV-like neuron-specific RNA binding protein 4 (ELAVL4), XIAP associated factor 1 (XAF1), monocyte to macrophage differentiation-associated (MMD), and chloride channel accessory 2 (CLCA2) genes. ELAVL4 regulates the radiosensitivity of the cancerous cells [20] , and it expresses in neuritis and lung tissue [21] . XAF1 acts as a tumor suppressor in colon cancer [22] . Another target, the CLCA2 protein expression status, could be an excellent way to identify primary SQCC and ADCC of the lung [23] . The previous study reported that the major target gene of miR-375 were the key members of calcium, insulin, Jak-STAT, MAPK, mTOR, PPAR, TGF-beta and Wnt pathways [24] . Table 4 and Table 5 shows the sensitivity and specificity obtained by ROC and DFA for miR-205 and miR-196b. The sensitivity and specificity of these two miRNAs were considerably poor compared to miR-375. Interestingly, there was an increasing pattern of sensitivity and specificity in the DFA when miR-205 or miR196b is associated with miR-375. The higher accuracy of miR-375 dragged the outcome towards higher sensitivity and specificity since miR-205 and miR-196b showed poor outcome when considered individually. In NSCLC, miR-205 is frequently amplified and differentially expressed [25, 26] . Although the biologic role of this miRNA in the development of SQCC was unclear, the previous study documented frequent up-regulation in SQCC [27] . Up-regulation of this miRNA inhibited the expression of PTEN, PHLPP2 and activated the AKT/FOXO3a, AKT/mTOR pathway that may lead to tumor cell proliferations, enhanced blood vessels formation and took part in EMT pathway [28] . However, in the current study, there was no significant difference in the expression level of miR-205 in both histologic subtypes (Training set: p = 0.3340, Validation set: p = 0.2351, Table 3 ). miR-196b was proven to be involved in disease in cancer pathogenesis [29] . Deregulation of this miRNA was common in multiple cancers including gastric cancer, glioblastoma, and breast cancer. The role of miR-196b in lung cancer remained an enigma. However, over-expression of miR-196b inhibits HOXA9 and induces the invasive properties in NSCLC cells [30] .
Conclusions
In conclusion, the present study trained and validated a binary diagnostic assay to identify SQCC and ADCC. miRNA could be used as an adjunctive diagnostic criterion in difficult cases where immunomorphology alone is inconclusive. A combine approach will certainly improve the overall diagnostic yield and better classification. miR-375 was proven to be the molecular marker of binary classification of NSCLC with 96.7% sensitivity and 93.1% specificity. ROC analysis set the cut-off value of 0.584 and considered SQCC if the Z score was positive. Interestingly, DFA for the training set and the validation set replicated the same result of ROC analysis, which only strengthens the diagnostic ability of miR-375. Further study is required on critical cases to validate the test. The current study is first in India to report the diagnostic ability of three miRNAs (miR-205, miR-196b, miR-375). In conclusion, this is an adjunctive assay which clinicians can use to confirm the classification of NSCLC side by side with HE and IHC in selected cases. However, it is also true that molecular approach may at times misclassify the tumor in a fraction of cases. Hence it will be a good idea to use this approach in conjunction with other lab tests. Similarities and dissimilarities of the present findings with findings of other research work may be attributed to the influence of differences in ethnic origins as well as differential environmental exposure to unknown carcinogenic agents. 
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